Matches in SemOpenAlex for { <https://semopenalex.org/work/W1505150426> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W1505150426 abstract "Objectives. Prophylaxis regimens for severe hemophilia A allowing more flexible dosing while maintaining efficacy may improve adherence and decrease the cost of prophylaxis. Here, we compared the clinical effectiveness of once- or twice-weekly versus ≥3-times-weekly prophylaxis with sucrose-formulated recombinant factor VIII (rFVIII-FS) in a real-world practice setting. Methods. Data from 3 postmarketing studies were pooled. Patients with severe hemophilia A receiving ≥1 prophylaxis infusion/wk of rFVIII-FS for ≥80% of a prophylaxis observation period (≥5 months) were included. Patients were categorized based on physician-assigned treatment regimens of 1-2 prophylaxis injections/wk (n = 63) or ≥3 prophylaxis injections/wk (n = 76). Descriptive statistics were determined for annualized bleeding rates (ABRs). Results. Median (quartile 1; quartile 3) ABR for all bleeds was 2.0 (0; 4.0) in the 1-2 prophylaxis injections/wk group and 3.9 (1.5; 9.3) in the ≥3 prophylaxis injections/wk group. Median ABRs for joint, spontaneous, and trauma-related bleeds were numerically lower with 1-2 prophylaxis injections/wk. As an estimate of prophylaxis success, 63% (≥3 prophylaxis injections/wk) to 84% of patients (1-2 prophylaxis injections/wk) had ≤4 annualized joint bleeds. Conclusions. Dosing flexibility and successful prophylaxis with rFVIII-FS were demonstrated. Very good bleeding control was achieved with both once-twice-weekly and ≥3-times-weekly prophylaxis dosing regimens." @default.
- W1505150426 created "2016-06-24" @default.
- W1505150426 creator A5001427023 @default.
- W1505150426 creator A5014574160 @default.
- W1505150426 creator A5016762682 @default.
- W1505150426 creator A5067220785 @default.
- W1505150426 creator A5068795219 @default.
- W1505150426 creator A5033295167 @default.
- W1505150426 date "2015-01-01" @default.
- W1505150426 modified "2023-09-24" @default.
- W1505150426 title "Sucrose-Formulated Recombinant Factor VIII Dosing Flexibility in Prophylaxis Regimens: Experience from Postmarketing Surveillance Studies" @default.
- W1505150426 cites W1522733324 @default.
- W1505150426 cites W1933263991 @default.
- W1505150426 cites W1976493649 @default.
- W1505150426 cites W2004012010 @default.
- W1505150426 cites W2006013990 @default.
- W1505150426 cites W2013607072 @default.
- W1505150426 cites W2021062770 @default.
- W1505150426 cites W2034317941 @default.
- W1505150426 cites W2088686527 @default.
- W1505150426 cites W2093390545 @default.
- W1505150426 cites W2111507766 @default.
- W1505150426 cites W2114341530 @default.
- W1505150426 cites W2143958714 @default.
- W1505150426 cites W2167801052 @default.
- W1505150426 doi "https://doi.org/10.1155/2015/431268" @default.
- W1505150426 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4556870" @default.
- W1505150426 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26356675" @default.
- W1505150426 hasPublicationYear "2015" @default.
- W1505150426 type Work @default.
- W1505150426 sameAs 1505150426 @default.
- W1505150426 citedByCount "2" @default.
- W1505150426 countsByYear W15051504262017 @default.
- W1505150426 countsByYear W15051504262021 @default.
- W1505150426 crossrefType "journal-article" @default.
- W1505150426 hasAuthorship W1505150426A5001427023 @default.
- W1505150426 hasAuthorship W1505150426A5014574160 @default.
- W1505150426 hasAuthorship W1505150426A5016762682 @default.
- W1505150426 hasAuthorship W1505150426A5033295167 @default.
- W1505150426 hasAuthorship W1505150426A5067220785 @default.
- W1505150426 hasAuthorship W1505150426A5068795219 @default.
- W1505150426 hasBestOaLocation W15051504261 @default.
- W1505150426 hasConcept C126322002 @default.
- W1505150426 hasConcept C141071460 @default.
- W1505150426 hasConcept C197636746 @default.
- W1505150426 hasConcept C197934379 @default.
- W1505150426 hasConcept C2777288759 @default.
- W1505150426 hasConcept C2778375690 @default.
- W1505150426 hasConcept C42219234 @default.
- W1505150426 hasConcept C44249647 @default.
- W1505150426 hasConcept C68443243 @default.
- W1505150426 hasConcept C71924100 @default.
- W1505150426 hasConceptScore W1505150426C126322002 @default.
- W1505150426 hasConceptScore W1505150426C141071460 @default.
- W1505150426 hasConceptScore W1505150426C197636746 @default.
- W1505150426 hasConceptScore W1505150426C197934379 @default.
- W1505150426 hasConceptScore W1505150426C2777288759 @default.
- W1505150426 hasConceptScore W1505150426C2778375690 @default.
- W1505150426 hasConceptScore W1505150426C42219234 @default.
- W1505150426 hasConceptScore W1505150426C44249647 @default.
- W1505150426 hasConceptScore W1505150426C68443243 @default.
- W1505150426 hasConceptScore W1505150426C71924100 @default.
- W1505150426 hasFunder F4320320303 @default.
- W1505150426 hasLocation W15051504261 @default.
- W1505150426 hasLocation W15051504262 @default.
- W1505150426 hasLocation W15051504263 @default.
- W1505150426 hasOpenAccess W1505150426 @default.
- W1505150426 hasPrimaryLocation W15051504261 @default.
- W1505150426 isParatext "false" @default.
- W1505150426 isRetracted "false" @default.
- W1505150426 magId "1505150426" @default.
- W1505150426 workType "article" @default.